What is ART-TG ?
The Technological Research Accelerator in Genomic Therapy (ART-TG) is a public biomedical research laboratory aiming to accelerate the development of innovative cell and gene therapy products towards clinical trials. ART-TG belongs to the "Integrator" network providing a one-stop shop for ATMP development.
What do we provide ?
A continuum of R&D in cell and gene therapy, including preclinical, clinical and service activities that are certified iso9001.
Our expertise on lentiviral vectors:
We develop lentiviral vector bioproduction processes ranging from small scale to pre-industrial preclinical grade, including analytics.
Genome Editing:
Specialized in genome-modifying tools, ART-TG hosts the Genomic and Genome Editing Quality Control Platform of the Genother biocluster in collaboration with the laboratories of M. Amendola (UMR_S951) and A. Miccio (Institute Imagine). We aim to support the development of safe Advanced Therapy Medicinal Products (ATMPs) utilizing LV or CRISPR-tools. See poster.
Inserm Transfert accompanies the partnerships of ART-TG.
Our location:
Within the Evry Genopole and Université Paris-Saclay campus, south of Paris, France.
Contact us:
For job opportunities go to our page JOBS
The Team
Anne Galy,
PharmD, PhD
Director ART-TG
ORCID 0000-0002-0153-4392
CV online
Genother partners
Sophie Amsellem-Bosq
D.Pharm, PhD
Head of Quality Management
Mario Amendola,
PhD
Genother Platform Lead
Expert Genome Editing
(ORCID)
Annarita Miccio,
PhD,
Genother Partner
Imagine Institute
(ORCID)
Our projects are funded by
